

Aldo P Maggioni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8504824/publications.pdf>

Version: 2024-02-01

804
papers

111,899
citations

381

138
h-index

218

317
g-index

853
all docs

853
docs citations

853
times ranked

66109
citing authors

#	ARTICLE	IF	CITATIONS
1	Methodology for the development of international clinical data standards for common cardiovascular conditions: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2023, 9, 161-168.	1.8	20
2	European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 4-13.	1.8	52
3	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 275-300.	0.8	11
4	Lead fixation mechanism impacts outcome of transvenous lead extraction: data from the European Lead Extraction CONTRolled Registry. <i>Europace</i> , 2022, 24, 817-827.	0.7	9
5	Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 469-477.	1.8	9
6	Pregnancy outcomes in women with a systemic right ventricle and transposition of the great arteries results from the ESC-EORP Registry of Pregnancy and Cardiac disease (ROPAC). <i>Heart</i> , 2022, 108, 117-123.	1.2	18
7	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 462-473.	1.4	8
8	Cost-Effectiveness of Posthospital Management of Acute Coronary Syndrome: A Real-World Investigation From Italy. <i>Value in Health</i> , 2022, 25, 185-193.	0.1	2
9	Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy. <i>Advances in Therapy</i> , 2022, 39, 314-327.	1.3	5
10	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2022, 145, 87-89.	1.6	28
11	Age-related changes in clinical characteristics and outcomes of chronic heart failure outpatients in a cardiology setting. A report from the Italian Network on Heart Failure. <i>International Journal of Cardiology</i> , 2022, 346, 36-44.	0.8	6
12	Mannose as a biomarker of coronary artery disease: Angiographic evidence and clinical significance. <i>International Journal of Cardiology</i> , 2022, 346, 86-92.	0.8	10
13	Atrial fibrillation ablation in heart failure: Findings from the ESC-EHRA EORP Atrial Fibrillation Ablation long-term (AFA LT) registry. <i>International Journal of Cardiology</i> , 2022, 346, 19-26.	0.8	2
14	Acute lower respiratory infections: real-world evidence of antibiotic prescription pattern and costs from a large administrative Italian database. <i>Family Practice</i> , 2022, 39, 669-677.	0.8	3
15	Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 497-509.	2.9	30
16	Why Do High-Risk Patients Develop or Not Develop Coronary Artery Disease? Metabolic Insights from the CAPIRE Study. <i>Metabolites</i> , 2022, 12, 123.	1.3	5
17	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction—Insights from the ESC-EHFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 335-350.	2.9	49
18	European Society of Cardiology: cardiovascular disease statistics 2021. <i>European Heart Journal</i> , 2022, 43, 716-799.	1.0	343

#	ARTICLE	IF	CITATIONS
19	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 143-168.	2.9	41
20	Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 9, 42-53.	1.8	11
21	Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. <i>American Heart Journal</i> , 2022, 248, 72-83.	1.2	15
22	Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). <i>European Heart Journal</i> , 2022, 43, 2185-2195.	1.0	12
23	Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009199.	1.6	3
24	Osteopontin as Candidate Biomarker of Coronary Disease despite Low Cardiovascular Risk: Insights from CAPIRE Study. <i>Cells</i> , 2022, 11, 669.	1.8	5
25	Heart failure and catheter ablation of atrial fibrillation: Navigating the difficult waters of heart failure phenotypes. <i>European Journal of Internal Medicine</i> , 2022, 99, 13-18.	1.0	2
26	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. <i>European Journal of Internal Medicine</i> , 2022, 99, 45-56.	1.0	5
27	Ischemic Cardiomyopathy versus Non-Ischemic Dilated Cardiomyopathy in Patients with Reduced Ejection Fraction Clinical Characteristics and Prognosis Depending on Heart Failure Etiology (Data) <i>TJ ETQq1 1 0.784314 15BT /Ov</i>		
28	Surgery and outcome of infective endocarditis in octogenarians: prospective data from the ESC EORP EURO-ENDO registry. <i>Infection</i> , 2022, 50, 1191-1202.	2.3	10
29	Clinical trials: conventional or pragmatic?. <i>European Journal of Heart Failure</i> , 2022, 24, 596-599.	2.9	2
30	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13773.	1.7	6
31	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. <i>Journal of the American Heart Association</i> , 2022, 11, e021327.	1.6	5
32	Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). <i>European Heart Journal</i> , 2022, 43, 2269-2285.	1.0	7
33	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	1.4	6
34	Reperfusion therapy for ST-elevation myocardial infarction complicated by cardiogenic shock: the European Society of Cardiology EurObservational programme acute cardiovascular care-European association of PCI ST-elevation myocardial infarction registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 481-490.	0.4	3
35	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events. <i>Annals of Medicine</i> , 2022, 54, 1036-1046.	1.5	9
36	Machine learning-derived major adverse event prediction of patients undergoing transvenous lead extraction: Using the ESC EHRA EORP European lead extraction CONTRolled ELECTRa registry. <i>Heart Rhythm</i> , 2022, 19, 885-893.	0.3	5

#	ARTICLE	IF	CITATIONS
37	Fifteen-Year Differences in Indications for Cardiac Resynchronization Therapy in International Guidelines—Insights from the Heart Failure Registries of the European Society of Cardiology. <i>Journal of Clinical Medicine</i> , 2022, 11, 3236.	1.0	2
38	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. <i>European Heart Journal</i> , 2022, 43, 3542-3552.	1.0	7
39	Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 486-495.	1.8	44
40	Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 432-445.	0.8	11
41	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 370-379.	0.8	83
42	Association of high-risk coronary atherosclerosis at CCTA with clinical and circulating biomarkers: Insight from CAPIRE study. <i>Journal of Cardiovascular Computed Tomography</i> , 2021, 15, 73-80.	0.7	16
43	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 229-237.	1.8	16
44	Effects of linagliptin on left ventricular dysfunction in patients with type 2 Diabetes and concentric left ventricular geometry: results of the DYDA 2 trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 8-17.	0.8	4
45	Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. <i>Europace</i> , 2021, 23, 174-183.	0.7	74
46	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 134-142.	1.8	3
47	Pregnancy outcomes in women with aortic coarctation. <i>Heart</i> , 2021, 107, 290-298.	1.2	18
48	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. <i>ESC Heart Failure</i> , 2021, 8, 95-105.	1.4	23
49	Pregnancy Outcomes in Women After Arterial Switch Operation for Transposition of the Great Arteries: Results From ROPAC (Registry of Pregnancy and Cardiac Disease) of the European Society of Cardiology EURObservational Research Programme. <i>Journal of the American Heart Association</i> , 2021, 10, e018176.	1.6	14
50	Methodological education in response to the quality of COVID-19 publications. <i>Pharmacological Research</i> , 2021, 164, 105381.	3.1	2
51	Impact of centre volume on atrial fibrillation ablation outcomes in Europe: a report from the ESC EHRA EORP Atrial Fibrillation Ablation Long-Term (AFA LT) Registry. <i>Europace</i> , 2021, 23, 49-58.	0.7	6
52	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 28-33.	1.8	2
53	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. <i>European Psychiatry</i> , 2021, 64, e7.	0.1	15
54	Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy/Myocarditis Registry. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 781-789.	0.5	10

#	ARTICLE	IF	CITATIONS
55	Risk stratification of patients undergoing transvenous lead extraction with the ELECTRa Registry Outcome Score (EROS): an ESC EHRA EORP European lead extraction ConTRolled ELECTRa registry analysis. <i>Europace</i> , 2021, 23, 1462-1471.	0.7	38
56	Temporal trends in the outcomes of acute heart failure: between consolatory evidences and real progress. <i>European Journal of Heart Failure</i> , 2021, 23, 432-435.	2.9	2
57	The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique. <i>Diabetes Therapy</i> , 2021, 12, 1445-1461.	1.2	5
58	Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007347.	1.6	17
59	Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. <i>Clinical Drug Investigation</i> , 2021, 41, 459-468.	1.1	5
60	Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13551.	1.7	8
61	The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTRolled ELECTRa Registry subanalysis" Author's reply. <i>Europace</i> , 2021, 23, 1149-1150.	0.7	1
62	The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. <i>European Journal of Heart Failure</i> , 2021, 23, 906-914.	2.9	130
63	Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. <i>Drugs and Aging</i> , 2021, 38, 341-346.	1.3	8
64	How to appropriately update practicing clinicians on innovations in heart failure therapy waiting for the new version of the guidelines?. <i>International Journal of Cardiology</i> , 2021, 329, 148-149.	0.8	0
65	Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003183.	1.6	7
66	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021, 23, 1040-1048.	2.9	70
67	Sex- and gender-specific precision medicine for chronic coronary syndromes: challenges and opportunities. <i>Kardiologia Polska</i> , 2021, 79, 373-375.	0.3	2
68	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1961-1973.	1.2	35
69	Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 1755.	1.0	1
70	The 70/30 Rule Between Men and Women" Disparity or Opportunity?. <i>JAMA Cardiology</i> , 2021, 6, 481.	3.0	0
71	Global Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e007901.	1.6	25
72	Insights into real-world treatment of cluster headache through a large Italian database: prevalence, prescription patterns, and costs. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1165-1171.	1.3	6

#	ARTICLE	IF	CITATIONS
73	Patient, hospital and country-level risk factors of all-cause mortality among patients with chronic heart failure: Prospective international cohort study. <i>PLoS ONE</i> , 2021, 16, e0250931.	1.1	2
74	Congenital heart disease in the ESC EORP Registry of Pregnancy and Cardiac disease (ROPAC). <i>International Journal of Cardiology Congenital Heart Disease</i> , 2021, 3, 100107.	0.2	5
75	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021, 143, 2129-2142.	1.6	101
76	Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. <i>European Journal of Internal Medicine</i> , 2021, 89, 65-75.	1.0	18
77	The prevalence and association of major ECG abnormalities with clinical characteristics and the outcomes of real-life heart failure patients in the Heart Failure Registries of the European Society of Cardiology. <i>Kardiologia Polska</i> , 2021, 79, 980-987.	0.3	4
78	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 14-23.	1.2	31
79	The hidden interplay between sex and COVID-19 mortality: the role of cardiovascular calcification. <i>GeroScience</i> , 2021, 43, 2215-2229.	2.1	16
80	Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology. <i>European Heart Journal</i> , 2021, 42, 4536-4549.	1.0	37
81	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3741-3752.	1.0	74
82	Metabolomic correlates of coronary atherosclerosis, cardiovascular risk, both or neither. Results of the 2 Å– 2 phenotypic CAPIRE study. <i>International Journal of Cardiology</i> , 2021, 336, 14-21.	0.8	9
83	Closing the Gap Between Populations Enrolled in Traditional Randomized Controlled Trials and Patients Encountered in Clinical Practice: The Case of Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e008840.	1.6	3
84	Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multicountry observational study. <i>Clinical Cardiology</i> , 2021, 44, 1333-1343.	0.7	3
85	Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 2058-2069.	2.9	20
86	Unexpected high mortality associated with very low lipoprotein(a) after acute myocardial infarction: Identifying the unknown. <i>European Journal of Internal Medicine</i> , 2021, 91, 26-28.	1.0	0
87	Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery. <i>JAMA Cardiology</i> , 2021, 6, 1042.	3.0	35
88	Efficacy of COVID-19 Vaccines Against Active Comparators or Inert Placebos. <i>JAMA Internal Medicine</i> , 2021, 181, 1257.	2.6	1
89	Coffee, Atrial Fibrillation, and Circulating Ceramides in Patients with Chronic Heart Failure. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 11236-11245.	2.4	5
90	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. <i>Circulation</i> , 2021, 144, 1380-1395.	1.6	24

#	ARTICLE	IF	CITATIONS
91	Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients. <i>Journal of Cardiovascular Computed Tomography</i> , 2021, 15, 421-430.	0.7	22
92	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management. <i>JAMA Cardiology</i> , 2021, 6, 1023.	3.0	10
93	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in Heart Failure with Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 627-635.	1.9	21
94	Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e022288.	1.6	8
95	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. <i>American Heart Journal</i> , 2021, 240, 73-80.	1.2	1
96	One year on: The impact of COVID-19 on clinical research. <i>European Journal of Internal Medicine</i> , 2021, 92, 24-27.	1.0	2
97	Prevalence, prescriptions, outcomes and costs of type 2 diabetes patients with or without prior coronary artery disease or stroke: a longitudinal 5-year claims-data analysis of over 7 million inhabitants. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110263.	1.1	5
98	Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine. <i>European Heart Journal Supplements</i> , 2021, 23, E13-E18.	0.0	10
99	Coronary Artery Disease in Patients Older than 35 and Eligible for Cardiovascular Secondary Prevention: An Italian Retrospective Observational Analysis of Healthcare Administrative Databases. <i>Journal of Clinical Medicine</i> , 2021, 10, 4708.	1.0	1
100	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021, 10, e021494.	1.6	13
101	Angiotensin Receptor Neprilysin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 1845-1855.	13.9	130
102	Cancer and Infective Endocarditis: Characteristics and Prognostic Impact. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 766996.	1.1	9
103	Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 553.	0.7	12
104	Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 790289.	1.1	8
105	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2141328.	2.8	30
106	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307.	0.8	28
107	The ESC ACCA EAPCI EORP acute coronary syndrome ST-elevation myocardial infarction registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 100-104.	1.8	9
108	Coronary Plaque Features on CTA Can Identify Patients at Increased Risk of Cardiovascular Events. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1704-1717.	2.3	64

#	ARTICLE	IF	CITATIONS
109	Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 313-323.	0.4	10
110	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 92-102.	2.9	81
111	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 315-329.	2.9	24
112	Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. <i>American Heart Journal</i> , 2020, 222, 93-104.	1.2	4
113	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , 2020, 43, 643-652.	4.3	38
114	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2020, 141, 338-351.	1.6	244
115	PCSK9 Inhibitors™ New Users: Analysis of Prescription Patterns and Patients™ Characteristics from an Italian Real-world Study. <i>Clinical Drug Investigation</i> , 2020, 40, 173-181.	1.1	21
116	European Society of Cardiology: Cardiovascular Disease Statistics 2019. <i>European Heart Journal</i> , 2020, 41, 12-85.	1.0	690
117	Ablation strategies for different types of atrial fibrillation in Europe: results of the ESC-EORP EHRA Atrial Fibrillation Ablation Long-Term registry. <i>Europace</i> , 2020, 22, 558-566.	0.7	11
118	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020, 43, 446-452.	4.3	63
119	Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people. <i>American Heart Journal</i> , 2020, 220, 12-19.	1.2	37
120	INtegration of care for reaching targetS In Diabetic patiEnts: Design of the INSIDE Study. <i>Diabetes Therapy</i> , 2020, 11, 359-367.	1.2	2
121	Hiperpotasemia en pacientes con insuficiencia cardiaca en España y su impacto en las recomendaciones. Registro ESC-EORP-HFA Heart Failure Long-Term. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 313-323.	0.6	16
122	COVID-19 trials in Italy: A call for simplicity, top standards and global pooling. <i>International Journal of Cardiology</i> , 2020, 318, 160-164.	0.8	5
123	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 175.	2.7	1
124	Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. <i>Drugs and Aging</i> , 2020, 37, 925-933.	1.3	23
125	ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patients. <i>ESC Heart Failure</i> , 2020, 7, 3013-3021.	1.4	19
126	Adapting to survive. <i>European Heart Journal</i> , 2020, 41, 3981-3983.	1.0	0

#	ARTICLE	IF	CITATIONS
127	Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). <i>European Heart Journal</i> , 2020, 41, 4092-4099.	1.0	174
128	The effect of centre volume and procedure location on major complications and mortality from transvenous lead extraction: an ESC EHRA EORP European Lead Extraction ConTRolled ELECTRa registry subanalysis. <i>Europace</i> , 2020, 22, 1718-1728.	0.7	22
129	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	1.0	15
130	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020, 41, 3787-3797.	1.0	101
131	Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction. <i>Circulation</i> , 2020, 142, 1725-1735.	1.6	77
132	Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. <i>ESC Heart Failure</i> , 2020, 7, 3601-3609.	1.4	11
133	Maintaining the balance between benefits and risks: The example of hyperkalemia in patients with heart failure. <i>Revista Portuguesa De Cardiologia</i> , 2020, 39, 543-544.	0.2	0
134	Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 841-844.	0.6	5
135	Cancer in chronic heart failure patients in the GISSI-HF trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13273.	1.7	8
136	Real-world data on new users of atypical antipsychotics: characterisation, prescription patterns, healthcare costs and early cardio-metabolic occurrences from a large Italian database. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1301-1310.	0.8	5
137	Admission of patients with STEMI since the outbreak of the COVID-19 pandemic: a survey by the European Society of Cardiology. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 210-216.	1.8	181
138	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. <i>American Heart Journal</i> , 2020, 227, 56-63.	1.2	24
139	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. <i>European Heart Journal</i> , 2020, 41, 1357-1364.	1.0	47
140	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020, 22, 1133-1143.	2.9	16
141	Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1675-1683.	2.9	24
142	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.	1.6	96
143	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	13.9	1,508
144	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. <i>ESC Heart Failure</i> , 2020, 7, 2098-2112.	1.4	23

#	ARTICLE	IF	CITATIONS
145	Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI-HF trial. <i>ESC Heart Failure</i> , 2020, 7, 3288-3297.	1.4	12
146	Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. <i>ESC Heart Failure</i> , 2020, 7, 727-736.	1.4	7
147	Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. <i>American Heart Journal</i> , 2020, 222, 157-165.	1.2	21
148	The Heart Failure Association Atlas: rationale, objectives, and methods. <i>European Journal of Heart Failure</i> , 2020, 22, 638-645.	2.9	23
149	Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study. <i>Diabetes Care</i> , 2020, 43, 843-851.	4.3	34
150	One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study. <i>European Journal of Internal Medicine</i> , 2020, 74, 55-60.	1.0	7
151	European Society of Cardiology: Cardiovascular Disease Statistics 2019 (Executive Summary). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 7-9.	1.8	39
152	Understanding the use of observational and randomized data in cardiovascular medicine. <i>European Heart Journal</i> , 2020, 41, 2571-2578.	1.0	24
153	The battle against COVID-19: mortality in Italy. <i>European Heart Journal</i> , 2020, 41, 2050-2052.	1.0	20
154	Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 906-910.	2.9	5
155	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-ORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1378-1389.	2.9	83
156	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-ORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	2.9	36
157	Testing longitudinal data for prognostication in ambulatory heart failure patients with reduced ejection fraction. A proof of principle from the GISSI-HF database. <i>International Journal of Cardiology</i> , 2020, 313, 89-96.	0.8	5
158	Cancer unmasked by bleeding during anticoagulant therapy: when a problem may become an opportunity. <i>European Heart Journal</i> , 2020, , .	1.0	1
159	Key words to be adopted for COVID-19 research. <i>European Heart Journal</i> , 2020, 41, 4229-4230.	1.0	4
160	Mega-trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020, 22, 1698-1707.	2.9	11
161	Prevalence Of familial hypercholesterolaemia (FH) in Italian Patients with coronary artery disease: The POSTER study. <i>Atherosclerosis</i> , 2020, 308, 32-38.	0.4	8
162	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. <i>Journal of Cardiac Failure</i> , 2020, 26, 932-943.	0.7	8

#	ARTICLE	IF	CITATIONS
163	Measuring multimorbidity inequality across Italy through the multisource comorbidity score: a nationwide study. <i>European Journal of Public Health</i> , 2020, 30, 916-921.	0.1	16
164	Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition. <i>Cardiac Failure Review</i> , 2020, 6, e28.	1.2	7
165	In-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: Results from the Polish part of the European Society of Cardiology Heart Failure Pilot and Long-Term Registries. <i>Cardiology Journal</i> , 2020, 27, 25-37.	0.5	5
166	Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. <i>Atherosclerosis Supplements</i> , 2020, 42, e59-e64.	1.2	8
167	Maintaining the balance between benefits and risks: The example of hyperkalemia in patients with heart failure. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2020, 39, 543-544.	0.2	0
168	Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study. <i>Europace</i> , 2019, 21, 230-238.	0.7	27
169	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	2.9	11
170	Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF EU trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1661-1662.	2.9	4
171	Stroke prevention by low-dose anticoagulation in patients with heart failure and sinus rhythm: is it worth the effort?. <i>European Heart Journal</i> , 2019, 40, 3602-3604.	1.0	3
172	Omega-3 Fatty Acids and Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 662-663.	1.9	0
173	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 862-874.	1.9	77
174	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019, 157, 682-691.e2.	0.6	299
175	Influence of risk factors in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 1365-1373.	0.5	15
176	Pantoprazole to Prevent Gastrointestinal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 403-412.e5.	0.6	108
177	Comparison of outcomes in infected cardiovascular implantable electronic devices between complete, partial, and failed lead removal: an ESC-EHRA-EORP ELECTRa (European Lead Extraction ConTrolled) registry. <i>Europace</i> , 2019, 21, 1876-1889.	0.7	10
178	Transvenous lead extraction procedures in women based on ESC-EHRA EORP European Lead Extraction ConTrolled ELECTRa registry: is female sex a predictor of complications?. <i>Europace</i> , 2019, 21, 1890-1899.	0.7	4
179	Impact of monitoring on detection of arrhythmia recurrences in the ESC-EHRA EORP atrial fibrillation ablation long-term registry. <i>Europace</i> , 2019, 21, 1802-1808.	0.7	11
180	Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. <i>European Heart Journal</i> , 2019, 40, 3222-3232.	1.0	421

#	ARTICLE	IF	CITATIONS
181	Angiotensinâ€“Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1609-1620.	13.9	1,485
182	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.	1.6	36
183	Contemporary Presentation and Management of Valvular Heart Disease. <i>Circulation</i> , 2019, 140, 1156-1169.	1.6	281
184	Major Bleeding in Patients With Coronary&Aor Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1519-1528.	1.2	30
185	EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials. <i>European Heart Journal</i> , 2019, 40, 2745-2749.	1.0	56
186	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	6.3	512
187	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	1.6	118
188	Audits of clinical practice should be encouraged. Use of loop diuretics in patients without a diagnosis of heart failure should be discouraged. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 289-290.	0.8	2
189	Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3296-3302.	1.8	11
190	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 529-537.	1.6	81
191	Sacubitril/valsartan eligibility and outcomes in the ESC&EORP&HFA Heart Failure Long&Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM&CHF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	2.9	35
192	Acute heart failure congestion and perfusion status&A&Amp;Impact of the clinical classification on in&hospital and long&term outcomes; insights from the ESC&EORP&HFA Heart Failure Long&Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	2.9	170
193	Appropriate prescriptions mean better outcomes: how can we improve ourselves?. <i>European Journal of Heart Failure</i> , 2019, 21, 930-931.	2.9	0
194	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , 2019, 285, 135-146.	0.4	227
195	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. <i>Europace</i> , 2019, 21, 1013-1022.	0.7	47
196	Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). <i>European Heart Journal</i> , 2019, 40, 3848-3855.	1.0	209
197	The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 202-207.	1.8	53
198	Clinical impact of antithrombotic therapy in transvenous lead extraction complications: a sub-analysis from the ESC-EORP EHRA ELECTRa (European Lead Extraction ConTRolled) Registry. <i>Europace</i> , 2019, 21, 1096-1105.	0.7	8

#	ARTICLE	IF	CITATIONS
199	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 824-835.	0.8	558
200	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2019, 4, 273.	3.0	100
201	Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 381, 2497-2505.	13.9	1,696
202	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 1586-1595.	2.9	24
203	Brachial pulse pressure in acute heart failure. Results of the Heart Failure Registry. <i>ESC Heart Failure</i> , 2019, 6, 1167-1177.	1.4	2
204	Factors associated with anticoagulation prescription in elderly patients with atrial fibrillation. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 660-663.	0.8	4
205	The use of antiplatelet agents after an acute coronary syndrome in a large community Italian setting of more than 12 million subjects. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 527-535.	0.4	8
206	Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF EU. <i>European Journal of Heart Failure</i> , 2019, 21, 322-333.	2.9	24
207	Major cardiac and vascular complications after transvenous lead extraction: acute outcome and predictive factors from the ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) registry. <i>Europace</i> , 2019, 21, 771-780.	0.7	56
208	Modes of death and prognostic outliers in chronic heart failure. <i>American Heart Journal</i> , 2019, 208, 100-109.	1.2	7
209	Atrial fibrillation history impact on catheter ablation outcome. Findings from the ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 313-320.	0.5	9
210	Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 77-86.	1.3	10
211	Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 334-342.	1.8	14
212	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. <i>European Journal of Heart Failure</i> , 2019, 21, 208-217.	2.9	60
213	Procedural outcomes associated with transvenous lead extraction in patients with abandoned leads: an ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) Registry Sub-Analysis. <i>Europace</i> , 2019, 21, 645-654.	0.7	39
214	Patterns of treatment with antiplatelet therapy after an acute coronary syndrome: Data from a large database in a community setting. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 836-846.	0.8	13
215	Background and design of the ACCA-EAPCI registry on ST-segment elevation myocardial infarction of the European Society of Cardiology. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 63-67.	0.4	8
216	Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2, C Trial). Rationale, Design, and Baseline Characteristics of the Study Population. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 547-555.	1.3	3

#	ARTICLE	IF	CITATIONS
217	Differences in clinical characteristics and one-year outcomes of hospitalized heart failure patients in succeeding European Society of Cardiology-Heart Failure Registries â€” Pilot and Long-Term. Polish Archives of Internal Medicine, 2019, 129, 106-116.	0.3	7
218	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	2.9	434
219	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. European Journal of Heart Failure, 2018, 20, 888-895.	2.9	93
220	Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis, 2018, 271, 120-127.	0.4	31
221	Cardiac resynchronization therapy in clinical practice: some interesting news but methodological advances are needed. European Journal of Heart Failure, 2018, 20, 1052-1054.	2.9	0
222	Management and prognosis of atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 172-179.	1.4	31
223	Lugano perspectives: final considerations. European Heart Journal Supplements, 2018, 20, C25-C26.	0.0	0
224	Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 205-215.	1.5	30
225	Contemporary stroke prevention strategies in 11â€™%096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace, 2018, 20, 747-757.	0.7	118
226	Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. European Heart Journal, 2018, 39, 1481-1495.	1.0	163
227	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. European Journal of Preventive Cardiology, 2018, 25, 377-387.	0.8	12
228	Arterial hypertension in patients with atrial fibrillation in Europe: A report from the EURObservational Research Programme pilot survey on atrial fibrillation. International Journal of Cardiology, 2018, 254, 136-141.	0.8	8
229	East Asia may have a better 1â€™year survival following an acute heart failure episode compared with Europe: results from an international observational cohort. European Journal of Heart Failure, 2018, 20, 1071-1075.	2.9	13
230	Overweight and obesity in patients with atrial fibrillation: Sex differences in 1â€™year outcomes in the EORPâ€™AF General Pilot Registry. Journal of Cardiovascular Electrophysiology, 2018, 29, 566-572.	0.8	23
231	Foreword by the Guest Editors of the new section of the IJC, â€œMigration and cardiovascular diseaseâ€” International Journal of Cardiology, 2018, 254, 353-355.	0.8	0
232	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes and Endocrinology, the, 2018, 6, 105-113.	5.5	451
233	Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. International Journal of Cardiology, 2018, 265, 162-168.	0.8	41
234	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal, 2018, 39, 1784-1793.	1.0	94

#	ARTICLE	IF	CITATIONS
235	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-oneÂtrial. European Journal of Cancer, 2018, 94, 126-137.	1.3	163
236	Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. Clinical Research in Cardiology, 2018, 107, 214-221.	1.5	28
237	Influence of socioeconomic factors on pregnancy outcome in women with structural heart disease. Heart, 2018, 104, 745-752.	1.2	10
238	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: REDÂCHF study. European Journal of Heart Failure, 2018, 20, 268-277.	2.9	42
239	A systematic review of in-hospital worsening heart failure as an endpoint in clinical investigations of therapy for acute heart failure. International Journal of Cardiology, 2018, 250, 215-222.	0.8	3
240	Preâ€discharge and early postâ€discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. European Journal of Heart Failure, 2018, 20, 281-291.	2.9	33
241	Longâ€term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2018, 20, 332-341.	2.9	69
242	Characteristics, treatments and 1â€year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2018, 20, 100-110.	2.9	86
243	A 'diamond' approach to personalized treatment of angina. Nature Reviews Cardiology, 2018, 15, 120-132.	6.1	105
244	Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensityâ€score matched study. European Journal of Heart Failure, 2018, 20, 345-354.	2.9	92
245	Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. European Journal of Heart Failure, 2018, 20, 677-686.	2.9	21
246	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 205-218.	6.3	426
247	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 219-229.	6.3	651
248	CardioScape mapping the cardiovascular funding landscape in Europe. European Heart Journal, 2018, 39, 2423-2430.	1.0	6
249	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. Journal of Diabetes Research, 2018, 2018, 1-9.	1.0	26
250	Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. European Journal of Heart Failure, 2018, 20, 1760-1763.	2.9	2
251	Judgement over an arbitrary line. European Heart Journal, 2018, 39, 4266-4268.	1.0	1
252	Effect of Onceâ€Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCLE Trial. Journal of the American Heart Association, 2018, 7, e009304.	1.6	19

#	ARTICLE	IF	CITATIONS
253	Improving Postdischarge Outcomes in Acute Heart Failure. <i>American Journal of Therapeutics</i> , 2018, 25, e475-e486.	0.5	17
254	Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 64 patients in the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Heart Journal</i> , 2018, 39, 4277-4284.	1.0	189
255	Reply. <i>JACC: Heart Failure</i> , 2018, 6, 810-811.	1.9	1
256	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. <i>JACC: Heart Failure</i> , 2018, 6, 452-462.	1.9	94
257	Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). <i>American Journal of Cardiology</i> , 2018, 122, 578-583.	0.7	12
258	Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. <i>European Journal of Internal Medicine</i> , 2018, 55, 28-34.	1.0	51
259	Risk of heart failure in diabetic patients receiving sulfonylureas. <i>European Journal of Heart Failure</i> , 2018, 20, 1371-1372.	2.9	1
260	Dose-dependent efficacy of β -blocker in patients with chronic heart failure and atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 273, 141-146.	0.8	13
261	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	1.6	117
262	Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. <i>International Journal of Cardiology</i> , 2018, 271, 68-74.	0.8	30
263	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the Tj ETQq1 1 0.784314rgBT /Overlock 10	0.7	6
264	Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 4030-4039.	1.0	19
265	Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. <i>European Heart Journal Supplements</i> , 2018, 20, F1-F74.	0.0	25
266	Target Population of Non-deferrable Surgery and Uncontrolled Severe Bleeding Related to Dabigatran. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 281-286.	1.3	7
267	Smartphones, barbershops, and pharmacists to improve adherence to drug treatment in chronic cardiovascular conditions: the end justifies all the means. <i>European Journal of Heart Failure</i> , 2018, 20, 1360-1362.	2.9	1
268	Do β -blockers improve one-year survival in heart failure patients with atrial fibrillation? Results from the ESC-HF Registry. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 649-657.	0.3	5
269	Impact of digoxin on risk of death in heart failure patients treated with β -blockers. Results from Polish part of ESC Heart Failure Long-Term Registry. <i>Kardiologia Polska</i> , 2018, 76, 1064-1072.	0.3	4
270	The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure. <i>Kardiologia Polska</i> , 2018, 76, 1336-1343.	0.3	14

#	ARTICLE	IF	CITATIONS
271	Heart failure patients with a previous coronary revascularization: results from the ESC-HF Registry. <i>Kardiologia Polska</i> , 2018, 76, 144-152.	0.3	1
272	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>Europace</i> , 2017, 19, euw150.	0.7	32
273	Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. <i>European Heart Journal</i> , 2017, 38, ehw564.	1.0	151
274	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (<sc>PPCM</sc>). <i>European Journal of Heart Failure</i> , 2017, 19, 1131-1141.	2.9	163
275	Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)â€”A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. <i>American Heart Journal</i> , 2017, 187, 182-190.	1.2	66
276	Use of lipid lowering drugs in patients at very high risk of cardiovascular events: An analysis on nearly 3,000,000 Italian subjects of the ARNO Observatory. <i>International Journal of Cardiology</i> , 2017, 246, 62-67.	0.8	9
277	Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. <i>Diabetes Care</i> , 2017, 40, 671-678.	4.3	103
278	Anemia at Hospital Admission and Its Relation to Outcomes in Patients With Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tff Cardiology, 2017, 119, 2021-2029.	0.7	21
279	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 1956-1964.	13.9	257
280	Relation between weight loss and causes of death in patients with cardiovascular disease. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 144-151.	0.6	9
281	Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the <sc>ESC</sc> Heart Failure Longâ€™Term Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1242-1254.	2.9	339
282	Streamlining cardiovascular clinical trials to improve efficiency and generalisability. <i>Heart</i> , 2017, 103, 1156-1162.	1.2	10
283	Influence of atrial fibrillation on postâ€™discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the <sc>ASTRONAUT</sc> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 552-562.	2.9	23
284	Improving public health by improving clinical trial guidelines and their application. <i>European Heart Journal</i> , 2017, 38, 1632-1637.	1.0	19
285	Patientâ€™reported outcomes in the <sc>SOLuble</sc> guanylate Cyclase <sc>stimulator</sc> in <sc>heart failure patientS</sc> with <sc>PRESERVED</sc> ejection fraction (<sc>SOCRATESâ€™PRESERVED</sc>) study. <i>European Journal of Heart Failure</i> , 2017, 19, 782-791.	2.9	84
286	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	0.8	133
287	Seattle Heart Failure and Proportional Riskâ€™Models Predict Benefit From Implantableâ€™Cardioverter-Defibrillators. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2606-2618.	1.2	79
288	Role of Bâ€™type Natriuretic Peptide and Nâ€™terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	75

#	ARTICLE	IF	CITATIONS
289	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , 2017, 38, 1119-1127.	1.0	285
290	The European Lead Extraction CONTROLled (ELECTRa) study: a European Heart Rhythm Association (EHRA) Registry of Transvenous Lead Extraction Outcomes. <i>European Heart Journal</i> , 2017, 38, 2995-3005.	1.0	339
291	Mechanisms linking empagliflozin to cardiovascular and renal protection. <i>International Journal of Cardiology</i> , 2017, 241, 450-456.	0.8	36
292	Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1574-1585.	2.9	568
293	Clinical and prognostic value of spot urinary creatinine in chronic heart failure—An analysis from GISSI-HF. <i>American Heart Journal</i> , 2017, 188, 189-195.	1.2	10
294	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCCEL). <i>American Heart Journal</i> , 2017, 187, 1-9.	1.2	49
295	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
296	The year in cardiology 2016: heart failure. <i>European Heart Journal</i> , 2017, 38, ehw638.	1.0	1
297	Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. <i>Europace</i> , 2017, 19, 1439-1448.	0.7	47
298	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1560-1562.	1.6	15
299	Heart failure with reduced ejection fraction. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17058.	18.1	136
300	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
301	Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1217-1227.	13.9	780
302	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonyleureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 887-897.	5.5	231
303	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	13.9	1,455
304	Use of statins and adverse outcomes in patients with atrial fibrillation: An analysis from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) general registry pilot phase. <i>International Journal of Cardiology</i> , 2017, 248, 166-172.	0.8	9
305	Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 580-589.	0.6	8
306	Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	19

#	ARTICLE	IF	CITATIONS
307	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 471-482.	1.9	238
308	Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51.	13.9	355
309	Uncovering difference: a glimpse at patients with heart failure in low-income and middle-income countries. The Lancet Global Health, 2017, 5, e634-e635.	2.9	2
310	Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella) Tj ETQq0 01orgBT /Overlock 10		
311	In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Long-Term Registry. European Journal of Heart Failure, 2017, 19, 54-65.	2.9	150
312	Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry. European Journal of Heart Failure, 2017, 19, 201-208.	2.9	126
313	Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure, 2017, 19, 271-279.	2.9	32
314	Are all people with diabetes and cardiovascular risk factors or microvascular complications at very high risk? Findings from the Risk and Prevention Study. Acta Diabetologica, 2017, 54, 123-131.	1.2	14
315	Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. European Journal of Heart Failure, 2017, 19, 673-681.	2.9	31
316	Progression of Renal Impairment and Chronic Kidney Disease in Chronic Heart Failure: An Analysis From GISSI-HF. Journal of Cardiac Failure, 2017, 23, 2-9.	0.7	26
317	Prevalence and Prognostic Impact of Chronic Obstructive Pulmonary Disease in Patients with Chronic Heart Failure: Data from the GISSI-HF Trial. Cardiology, 2017, 136, 128-137.	0.6	46
318	The European Society of Cardiology ACCA-EAPCI Registry on ST elevation myocardial infarction. European Heart Journal, 2017, 38, 138-139.	1.0	3
319	Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure. Circulation Journal, 2017, 81, 1543-1546.	0.7	0
320	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic therapeutic pathway in Italy. European Heart Journal Supplements, 2017, 19, D3-D54.	0.0	19
321	Therapeutic Strategies and Health Costs of Patients Admitted for a Cardiovascular Event in Italy. Global & Regional Health Technology Assessment, 2016, 3, GRHTA.5000221.	0.2	3
322	Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis. Patient Preference and Adherence, 2016, 10, 523.	0.8	8
323	European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. European Journal of Heart Failure, 2016, 18, 613-625.	2.9	538
324	The European Society of Cardiology Heart Failure Association Annual Congress. European Journal of Heart Failure, 2016, 18, 454-455.	2.9	0

#	ARTICLE	IF	CITATIONS
325	Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac disease: results of a registry from the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 523-533.	2.9	113
326	Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 859-868.	2.9	36
327	Diagnosis, Clinical Course, and 1-Year Outcome in Patients Hospitalized for Heart Failure With Preserved Ejection Fraction (from the Polish Cohort of the European Society of Cardiology Heart) <i>Tj ETQq1 1 0.784614 rgBT 10verloc</i>		
328	Outcome improvement of patients with heart failure and reduced ejection fraction: has it ended in the new millennium?. <i>European Journal of Heart Failure</i> , 2016, 18, 512-513.	2.9	1
329	Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. <i>Scientific Reports</i> , 2016, 6, 30271.	1.6	51
330	Real-world cost effectiveness of MitraClip combined with Medical Therapy Versus Medical therapy alone in patients with moderate or severe mitral regurgitation. <i>International Journal of Cardiology</i> , 2016, 209, 153-160.	0.8	37
331	Real-world™ atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. <i>Europace</i> , 2016, 19, euw112.	0.7	55
332	Risk of Pregnancy in Moderate and Severe Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1727-1737.	1.2	113
333	Epidemiology of Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 15-33.	0.9	79
334	Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology. <i>International Journal of Cardiology</i> , 2016, 220, 131-136.	0.8	45
335	Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	20
336	Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: A report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>American Heart Journal</i> , 2016, 181, 83-91.	1.2	38
337	Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease (<scp>ROPAC</scp>) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 1119-1128.	2.9	164
338	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016, 37, 2105-2114.	1.0	274
339	The real-world evidence of heart failure: findings from 41 413 patients of the <scp>ARNO</scp> database. <i>European Journal of Heart Failure</i> , 2016, 18, 402-410.	2.9	120
340	Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT. <i>European Stroke Journal</i> , 2016, 1, 93-100.	2.7	1
341	Coronary atherosclerosis in outlier subjects at the opposite extremes of traditional risk factors: Rationale and preliminary results of the Coronary Atherosclerosis in outlier subjects: Protective and novel Individual Risk factors Evaluation (CAPIRE) study. <i>American Heart Journal</i> , 2016, 173, 18-26.	1.2	14
342	Cyclosporine A in Reperused Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 365-374.	1.2	144

#	ARTICLE	IF	CITATIONS
343	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. American Heart Journal, 2016, 174, 103-110.	1.2	82
344	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. American Journal of Cardiology, 2016, 117, 1144-1150.	0.7	23
345	Regional differences in referral, procedures, and outcome after ablation for atrial fibrillation in Europe: a report from the Atrial Fibrillation Ablation Pilot Registry of the European Society of Cardiology. Europace, 2016, 18, 191-200.	0.7	13
346	Usefulness of High-Sensitivity Cardiac Troponin T for the Identification of Outlier Patients With Diffuse Coronary Atherosclerosis and Low-Risk Factors. American Journal of Cardiology, 2016, 117, 1397-1404.	0.7	14
347	The use of HeartQoL in patients with coronary heart disease: Association with risk factors and European reference values. The EUROASPIRE IV study of the European Society of Cardiology. European Journal of Preventive Cardiology, 2016, 23, 1174-1186.	0.8	14
348	Real-world™ management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme Atrial Fibrillation (EORP-AF) General Pilot Registry. Europace, 2016, 18, 648.1-657.	0.7	61
349	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	15
350	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care, 2016, 39, 709-716.	4.3	55
351	Prognostic impact of in-hospital hyperglycemia in hospitalized patients with acute heart failure: Results of the IN-HF (Italian Network on Heart Failure) Outcome registry. International Journal of Cardiology, 2016, 203, 587-593.	0.8	33
352	European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. European Heart Journal, 2016, 37, 164-173.	1.0	56
353	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). European Heart Journal, 2016, 37, 152-160.	1.0	29
354	Validity and reliability of the HeartQoL questionnaire in a large sample of stable coronary patients: The EUROASPIRE IV Study of the European Society of Cardiology. European Journal of Preventive Cardiology, 2016, 23, 714-721.	0.8	46
355	Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 377-382.	0.2	28
356	Clinical characteristics and predictors of one-year outcome of heart failure patients with atrial fibrillation compared to heart failure patients in sinus rhythm. Kardiologia Polska, 2016, 74, 251-261.	0.3	21
357	Age-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe. JACC: Clinical Electrophysiology, 2015, 1, 326-334.	1.3	52
358	Global variation in clinical profile, management, and postdischarge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. European Journal of Heart Failure, 2015, 17, 591-600.	2.9	58
359	Recommendations on prehospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure, 2015, 17, 544-558.	2.9	315
360	Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. European Journal of Heart Failure, 2015, 17, 1114-1123.	2.9	49

#	ARTICLE	IF	CITATIONS
361	The 30-day metric in acute heart failure revisited: data from <scp>IN-HF</scp> Outcome, an Italian nationwide cardiology registry. <i>European Journal of Heart Failure</i> , 2015, 17, 1032-1041.	2.9	32
362	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the <scp>EVEREST</scp> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1022-1031.	2.9	52
363	Ten years differences in recently onset atrial fibrillation and flutter incidence and management. <i>Monaldi Archives for Chest Disease</i> , 2015, 82, 153-9.	0.3	6
364	Clinical research Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) – Polish population. <i>Archives of Medical Science</i> , 2015, 4, 743-750.	0.4	8
365	EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)–EURObservational Research Program of the European Society of Cardiology. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 466-470.	0.5	35
366	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , 2015, 36, 1106-1114.	1.0	53
367	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. <i>European Heart Journal</i> , 2015, 36, 1958-1966.	1.0	105
368	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88
369	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2015, 115, 790-796.	0.7	37
370	Clinical characteristics and management of hospitalized and ambulatory patients with heart failure – results from ESC heart failure long-term registry – Egyptian cohort. <i>ESC Heart Failure</i> , 2015, 2, 159-167.	1.4	34
371	Appropriateness of Prescriptions of Recommended Treatments in Organisation for Economic Co-operation and Development Health Systems: Findings Based on the Long-Term Registry of the European Society of Cardiology on Heart Failure. <i>Value in Health</i> , 2015, 18, 1098-1104.	0.1	11
372	Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 551-561.	1.3	11
373	Asymptomatic Atrial Fibrillation: Clinical Correlates, Management, and Outcomes in the EORP-AF Pilot General Registry. <i>American Journal of Medicine</i> , 2015, 128, 509-518.e2.	0.6	242
374	Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the <scp>ASTRONAUT</scp> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 98-108.	2.9	30
375	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2015, 17, 194-206.	0.7	41
376	Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. <i>Lancet</i> , The, 2015, 385, 1397-1405.	6.3	1,112
377	Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 441-452.	0.4	81
378	Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without revascularization: insights from the EYESHOT study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 168-178.	1.4	22

#	ARTICLE	IF	CITATIONS
379	Regular Wine Consumption in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 428-437.	1.6	26
380	Pregnancy in Women With a Mechanical Heart Valve. <i>Circulation</i> , 2015, 132, 132-142.	1.6	274
381	Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Studyâ€Heart Failure (ARTSâ€HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015, 17, 224-232.	2.9	74
382	Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individualâ€level reanalysis of CORONA and GISSIâ€HF. <i>European Journal of Heart Failure</i> , 2015, 17, 434-441.	2.9	39
383	Prognostic impact of metabolic syndrome in patients with chronic heart failure: Data from GISSI-HF trial. <i>International Journal of Cardiology</i> , 2015, 178, 85-90.	0.8	18
384	Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. <i>International Journal of Obesity</i> , 2015, 39, 849-857.	1.6	7
385	Secondary prevention after acute myocardial infarction: Drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1548-1556.	0.8	42
386	Heart failure in patients with atrial fibrillation in Europe: a report from the <sc>EURObservational</sc> Research Programme Pilot survey on Atrial Fibrillation. <i>European Journal of Heart Failure</i> , 2015, 17, 570-582.	2.9	68
387	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation. <i>Circulation</i> , 2015, 131, 1486-1494.	1.6	92
388	Granulocyte-colony stimulating factor for large anterior ST-elevation myocardial infarction: Rationale and design of the prospective randomized phase III STEM-AMI OUTCOME trial. <i>American Heart Journal</i> , 2015, 170, 652-658.e7.	1.2	9
389	Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. <i>Europace</i> , 2015, 17, 1777-1786.	0.7	128
390	Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. <i>Circulation</i> , 2015, 132, 2297-2304.	1.6	64
391	Epidemiology of Heart Failure in Europe. <i>Heart Failure Clinics</i> , 2015, 11, 625-635.	1.0	68
392	Reply to comment on Cost of poor adherence to anti-hypertensive therapy in five European country. <i>European Journal of Health Economics</i> , 2015, 16, 909-911.	1.4	1
393	A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model. <i>Heart Rhythm</i> , 2015, 12, 2069-2077.	0.3	77
394	Rationale and design of GISSI OUTLIERS VAR Study in bicuspid aortic valve patients: Prospective longitudinal, multicenter study to investigate correlation between surgical, echo distinctive features, histologic and genetic findings in phenotypically homogeneous outlier cases. <i>International Journal of Cardiology</i> , 2015, 199, 180-185.	0.8	3
395	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015, 373, 2247-2257.	13.9	1,856
396	Response to Letter Regarding Article, â€Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nellâ€™Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.â€ Circulation, 2015, 132, e358.	1.6	2

#	ARTICLE	IF	CITATIONS
397	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2015, 314, 2251.	3.8	288
398	Short- and long-term mortality and hospital readmissions among patients with new hospitalization for heart failure: A population-based investigation from Italy. International Journal of Cardiology, 2015, 181, 81-87.	0.8	37
399	Cost of poor adherence to anti-hypertensive therapy in five European countries. European Journal of Health Economics, 2015, 16, 65-72.	1.4	66
400	Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace, 2015, 17, 24-31.	0.7	164
401	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, The, 2015, 385, 351-361.	6.3	562
402	Hospital Readmissions of Patients with Heart Failure: The Impact of Hospital and Primary Care Organizational Factors in Northern Italy. PLoS ONE, 2015, 10, e0127796.	1.1	27
403	The Economic Crisis and Acute Myocardial Infarction: New Evidence Using Hospital-Level Data. PLoS ONE, 2015, 10, e0142810.	1.1	8
404	Upstream Treatment of Atrial Fibrillation with n-3 Polyunsaturated Fatty Acids: Myth or Reality?. Arrhythmia and Electrophysiology Review, 2015, 4, 163.	1.3	6
405	The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. International Journal of Obesity, 2014, 38, 1110-1114.	1.6	155
406	Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF) Tj ETQq0 0 0.0gBT /Ozok 10 T	0.8	204
407	Rationale and design of the <sc>SOLuble</sc> guanylate Cyclase <sc>stimulatoR</sc> in <sc>heArT failure</sc> Studies (<sc>SOCRATES</sc>). European Journal of Heart Failure, 2014, 16, 1026-1038.	2.9	119
408	<sc>EURObservational</sc> Research Programme: a worldwide registry on peripartum cardiomyopathy (<sc>PPCM</sc>) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on <sc>PPCM</sc>. European Journal of Heart Failure, 2014, 16, 583-591.	2.9	99
409	Burden of new hospitalization for heart failure: a population-based investigation from Italy. European Journal of Heart Failure, 2014, 16, 729-736.	2.9	72
410	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. JAMA - Journal of the American Medical Association, 2014, 312, 1006.	3.8	375
411	Direct healthcare costs and resource consumption after acute coronary syndrome: a real-life analysis of an Italian subpopulation. European Journal of Preventive Cardiology, 2014, 21, 1090-1096.	0.8	8
412	Predictors of mortality in acute heart failure and severe renal dysfunction. Does formula for glomerular filtration rate have any impact? Data from IN-HF outcome registry. International Journal of Cardiology, 2014, 172, e96-e97.	0.8	2
413	Use and misuse of statins after ACS: analysis of a prescription database of a community setting of 2,042,968 subjects. European Journal of Preventive Cardiology, 2014, 21, 1109-1116.	0.8	8
414	â€Real-Worldâ€™ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey. American Journal of Medicine, 2014, 127, 519-529.e1.	0.6	144

#	ARTICLE	IF	CITATIONS
415	Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. <i>European Journal of Heart Failure</i> , 2014, 16, 103-111.	2.9	355
416	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014, 16, 308-319.	0.7	280
417	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Trial. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1431-1438.	1.0	304
418	Cardiac medication during pregnancy, data from the ROPAC. <i>International Journal of Cardiology</i> , 2014, 177, 124-128.	0.8	85
419	The Anp genetic variant Rs5068 and circulating levels of natriuretic peptides in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2014, 176, 1249-1251.	0.8	4
420	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	1.6	34
421	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014, 35, 2797-2815.	1.0	304
422	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014, 114, 743-750.	0.7	8
423	The Atrial Fibrillation Ablation Pilot Study: an European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. <i>European Heart Journal</i> , 2014, 35, 1466-1478.	1.0	180
424	Body Mass Index and Mortality in Acutely Decompensated Heart Failure Across the World. <i>Journal of the American College of Cardiology</i> , 2014, 63, 778-785.	1.2	213
425	Newest additions to heart failure treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1849-1861.	0.9	1
426	Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. <i>International Journal of Cardiology</i> , 2014, 172, 588-594.	0.8	83
427	Overweight, obesity, and outcomes: fat mass and beyond. <i>Lancet</i> , 2014, 383, 935-936.	6.3	37
428	Impact of renal dysfunction on the Seattle Heart Failure Model. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 163-169.	0.3	4
429	In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs.) <i>Journal of the American College of Cardiology</i> , 2014, 173, 163-169.	0.8	98
430	Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology-Heart Failure pilot survey. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 204887261452701.	0.4	20
431	Treatment with inotropes and related prognosis in acute heart failure: Contemporary data from the Italian Network on Heart Failure (IN-HF) Outcome registry. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1056-1065.	0.3	23
432	Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. <i>Journal of Invasive Cardiology</i> , 2014, 26, 563-9.	0.4	24

#	ARTICLE	IF	CITATIONS
433	Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: Data from the GISSI-AF trial. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 28.	0.7	38
434	Decision making for oral anticoagulants in atrial fibrillation: The ATA-AF study. <i>European Journal of Internal Medicine</i> , 2013, 24, 324-332.	1.0	15
435	Outcomes, Health Costs and Use of Antiplatelet Agents in 7,082 Patients Admitted for an Acute Coronary Syndrome Occurring in a Large Community Setting. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 333-340.	1.3	5
436	Left ventricular dysfunction and outcome at two-year follow-up in patients with type 2 diabetes: The DYDA study. <i>Diabetes Research and Clinical Practice</i> , 2013, 101, 236-242.	1.1	15
437	Wine consumption and risk of cardiovascular events after myocardial infarction: Results from the GISSI-Prevenzione trial. <i>International Journal of Cardiology</i> , 2013, 163, 282-287.	0.8	42
438	Should we revise our approach to 'optimal medical therapy'? The case of chronic heart failure. <i>European Heart Journal</i> , 2013, 34, 2792-2794.	1.0	14
439	Tubular Damage and Worsening Renal Function in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 417-424.	1.9	87
440	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013, 18, 107-122.	1.7	51
441	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. <i>European Journal of Heart Failure</i> , 2013, 15, 947-959.	2.9	75
442	Learning from recent trials and shaping the future of acute heart failure trials. <i>American Heart Journal</i> , 2013, 166, 629-635.	1.2	30
443	ELECTRa (European Lead Extraction ConTRolled) Registry—Shedding light on transvenous lead extraction real-world practice in Europe. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2013, 24, 171-175.	0.3	23
444	Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. <i>International Journal of Cardiology</i> , 2013, 168, 3691-3697.	0.8	20
445	CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials. <i>European Journal of Heart Failure</i> , 2013, 15, 747-755.	2.9	16
446	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2013, 15, 679-689.	2.9	30
447	Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 61-68.	2.9	21
448	Association Between Elevated Blood Glucose and Outcome in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 820-829.	1.2	111
449	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687.	0.8	97
450	Predictors of Mortality in 6975 Patients With Chronic Heart Failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2013, 6, 31-39.	1.6	101

#	ARTICLE	IF	CITATIONS
451	Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review. <i>Clinical Research in Cardiology</i> , 2013, 102, 1-10.	1.5	9
452	The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. <i>JACC: Heart Failure</i> , 2013, 1, 488-496.	1.9	58
453	Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: Insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. <i>American Heart Journal</i> , 2013, 165, 216-225.	1.2	82
454	Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. <i>American Heart Journal</i> , 2013, 166, 935-940.e1.	1.2	35
455	Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: The ATA AF study. <i>International Journal of Cardiology</i> , 2013, 167, 2895-2903.	0.8	63
456	n-3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI-HF trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1289-1295.	2.9	33
457	Uric acid: A cardiovascular risk factor in patients with recent myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 167, 262-269.	0.8	41
458	Relationship Between Clinical Trial Site Enrollment With Participant Characteristics, Protocol Completion, and Outcomes. <i>Journal of the American College of Cardiology</i> , 2013, 61, 571-579.	1.2	58
459	Percutaneous revascularization and long term clinical outcomes of diabetic patients randomized in the Occluded Artery Trial (OAT). <i>International Journal of Cardiology</i> , 2013, 168, 2416-2422.	0.8	10
460	n-3PUFA and Holter-derived autonomic variables in patients with heart failure: Data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) Holter substudy. <i>Heart Rhythm</i> , 2013, 10, 226-232.	0.3	23
461	Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: Relation with fish intake, circulating biomarkers, and mortality. <i>American Heart Journal</i> , 2013, 165, 208-215.e4.	1.2	60
462	Relation of Serum Magnesium Levels and Postdischarge Outcomes in Patients Hospitalized for Heart Failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2013, 112, 1763-1769.	0.7	8
463	Prognostic Value of Cardiac Troponin I Measured With a Highly Sensitive Assay in Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1240-1249.	1.2	271
464	Prevalence and prognostic role of anaemia in patients with acute heart failure and preserved or depressed ventricular function. <i>Internal and Emergency Medicine</i> , 2013, 8, 147-155.	1.0	18
465	Treatment of Anemia with Darbeoetin Alfa in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2013, 368, 1210-1219.	13.9	462
466	Clinical Course of Patients With Hyponatremia and Decompensated Systolic Heart Failure and the Effect of Vasopressin Receptor Antagonism With Tolvaptan. <i>Journal of Cardiac Failure</i> , 2013, 19, 390-397.	0.7	130
467	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1125.	3.8	297
468	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	1.0	3,915

#	ARTICLE	IF	CITATIONS
469	Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. <i>European Heart Journal</i> , 2013, 34, 835-843.	1.0	418
470	Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Heart Journal</i> , 2013, 34, 3117-3127.	1.0	53
471	Cardiovascular Biomarkers, Cardiac Dysfunction, and Outcomes in Patients With Type 2 Diabetes: A Prospective, Multicenter Study. <i>Diabetes Care</i> , 2013, 36, e137-e138.	4.3	3
472	Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. <i>European Heart Journal</i> , 2013, 34, 1404-1413.	1.0	921
473	Management of patients with acute coronary syndromes in real-world practice in Italy: an outcome research study focused on the use of AntiThrombotic Agents: the MANTRA registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013, 2, 27-34.	0.4	24
474	Multicenter Prospective Observational Study on Acute and Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 473-481.	1.6	170
475	Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1228-1235.	2.9	51
476	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2013, 15, 1173-1184.	2.9	533
477	Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1401-1411.	2.9	119
478	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	2.9	182
479	Baseline characteristics of patients in the Reduction of Events with Darbeoetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	2.9	24
480	Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 194-202.	2.9	155
481	EUR-Observational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2013, 15, 808-817.	2.9	645
482	Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1382-1389.	2.9	21
483	Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. <i>European Heart Journal</i> , 2013, 34, 657-665.	1.0	378
484	Association of Arginine Vasopressin Levels With Outcomes and the Effect of V2 Blockade in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2013, 6, 47-52.	1.6	61
485	Adaptive servo ventilation reduces central sleep apnea in chronic heart failure patients. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 296-300.	0.6	15
486	Uric Acid as a Risk Factor for Cardiovascular Disease and Mortality in Overweight/Obese Individuals. <i>PLoS ONE</i> , 2013, 8, e59121.	1.1	54

#	ARTICLE	IF	CITATIONS
487	The 2011-12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients. <i>EuroIntervention</i> , 2013, 8, 1362-1371.	1.4	168
488	In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry. <i>Journal of Invasive Cardiology</i> , 2013, 25, 170-6.	0.4	8
489	The management of acute myocardial infarction in the cardiological intensive care units in Italy: the "BLITZ 4 Qualit" campaign for performance measurement and quality improvement. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2012, 1, 143-152.	0.4	36
490	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012, 33, 1787-1847.	1.0	5,233
491	Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 935-943.	0.8	28
492	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2012, 14, 1056-1066.	2.9	105
493	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	1.0	5,034
494	Targeting myocardial substrate metabolism in heart failure: potential for new therapies. <i>European Journal of Heart Failure</i> , 2012, 14, 120-129.	2.9	130
495	Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. <i>European Journal of Heart Failure</i> , 2012, 14, 302-311.	2.9	159
496	Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. <i>European Journal of Heart Failure</i> , 2012, 14, 992-999.	2.9	91
497	Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure. <i>Circulation</i> , 2012, 125, 280-288.	1.6	209
498	Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator. <i>Circulation</i> , 2012, 126, 2402-2407.	1.6	66
499	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012, 33, 2782-2795.	1.0	148
500	ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. <i>Europace</i> , 2012, 14, 1094-1103.	0.7	123
501	The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2012, 33, 1750-1757.	1.0	652
502	CardioPulse Articles. <i>European Heart Journal</i> , 2012, 33, 2237-2245.	1.0	1
503	Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. <i>Europace</i> , 2012, 14, 666-674.	0.7	114
504	Elderly patients with acute coronary syndromes admitted to Italian intensive cardiac care units. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 165-174.	0.6	9

#	ARTICLE	IF	CITATIONS
505	Inhibition of the renin-angiotensin-aldosterone system. <i>Journal of Hypertension</i> , 2012, 30, 647-654.	0.3	15
506	Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 415-422.	0.6	29
507	Shooting beyond score. <i>Journal of Hypertension</i> , 2012, 30, 1909-1910.	0.3	1
508	Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. <i>European Journal of Heart Failure</i> , 2012, 14, 185-192.	2.9	38
509	Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. <i>European Journal of Heart Failure</i> , 2012, 14, 1208-1217.	2.9	112
510	A review of the epidemiological profile of patients with atrial fibrillation and heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1133-1140.	0.6	8
511	Clinical epidemiology, management and outcome of acute coronary syndromes in the Italian network on acute coronary syndromes (IN-ACS Outcome study). <i>Acute Cardiac Care</i> , 2012, 14, 71-80.	0.2	23
512	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.	2.9	2,307
513	Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index: Data from the IN-CHF Registry. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 442-448.	1.1	12
514	Acute Coronary Syndrome in Patients With Atrial Fibrillation. <i>Circulation</i> , 2012, 126, 1176-1178.	1.6	3
515	n-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. <i>New England Journal of Medicine</i> , 2012, 367, 309-318.	13.9	810
516	The Impact of Chronic Obstructive Pulmonary Disease in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction: An Analysis of the EVEREST Trial. <i>Journal of Cardiac Failure</i> , 2012, 18, 515-523.	0.7	62
517	Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 750-758.	1.6	89
518	RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers. <i>BMC Cardiovascular Disorders</i> , 2012, 12, 85.	0.7	19
519	Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: Findings from the EVEREST Trial. <i>American Heart Journal</i> , 2012, 164, 884-892.e2.	1.2	24
520	Prognostic Value of Monocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2012, 110, 1657-1662.	0.7	14
521	Gender Does Not Affect Postdischarge Outcomes in Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) <i>Tj ETQq1 1 0.7843 10.7gBT / Overlock 10</i>	0.7	14
522	Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 997-1006.	1.1	42

#	ARTICLE	IF	CITATIONS
523	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Revista Española De Cardiología, 2012, 65, 938.e1-938.e59.	0.6	31
524	Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia, 2012, 55, 2348-2355.	2.9	62
525	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	13.9	1,426
526	Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2012, 26, 131-143.	1.3	10
527	A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Failure Reviews, 2012, 17, 485-509.	1.7	100
528	Comparison of Late Results of Percutaneous Coronary Intervention Among Stable Patients ≥ 65 Versus < 65 Years of Age With an Occluded Infarct Related Artery (from the Occluded Artery Trial). American Journal of Cardiology, 2012, 109, 614-619.	0.7	2
529	Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study. European Journal of Heart Failure, 2011, 13, 755-764.	2.9	19
530	Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. European Journal of Heart Failure, 2011, 13, 148-153.	2.9	80
531	Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. European Journal of Heart Failure, 2011, 13, 1253-1260.	2.9	32
532	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. New England Journal of Medicine, 2011, 365, 699-708.	13.9	918
533	Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. American Heart Journal, 2011, 161, 338-343.e1.	1.2	53
534	Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: Analysis from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Trials. American Heart Journal, 2011, 161, 1067-1072.	1.2	37
535	Rationale, design, and results from RENO-DEFEND 1: A randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. American Heart Journal, 2011, 161, 1012-1023.e3.	1.2	15
536	Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. American Heart Journal, 2011, 161, 1156-1162.	1.2	17
537	Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico "Atrial Fibrillation (GISSI-AF) trial. American Heart Journal, 2011, 162, 382-389.	1.2	28
538	Study design and rationale for the Stabilization of pLaques using Darapladib "Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. American Heart Journal, 2011, 162, 613-619.e1.	1.2	77
539	Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 981-992.	13.9	7,537
540	Effect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: The AREA-in-CHF study. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 783-791.	1.1	20

#	ARTICLE	IF	CITATIONS
541	Role of renin-angiotensin system inhibitors in atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 374.	0.6	0
542	Relation between serum sodium levels and prognosis in outpatients with chronic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 723-731.	0.6	19
543	Adiponectin in chronic heart failure: influence of diabetes and genetic variants. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1330-1338.	1.7	14
544	Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-Atrial Fibrillation Trial. <i>Journal of Internal Medicine</i> , 2011, 269, 160-171.	2.7	63
545	Opposing Effects of β Blockers and Angiotensin-Converting Enzyme Inhibitors on Development of New-Onset Diabetes Mellitus in Patients With Stable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2011, 107, 1705-1709.	0.7	15
546	Effect of Aliskiren in Patients with Heart Failure According to Background Dose of ACE Inhibitor: A Retrospective Analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) Trial. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 315-321.	1.3	6
547	Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. <i>European Heart Journal</i> , 2011, 32, 2563-2572.	1.0	116
548	Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). <i>European Journal of Heart Failure</i> , 2011, 13, 100-106.	2.9	68
549	Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. <i>European Journal of Heart Failure</i> , 2011, 13, 746-754.	2.9	30
550	Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 415-423.	3.1	28
551	Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. <i>European Heart Journal</i> , 2011, 32, 1227-1234.	1.0	130
552	Response to Letter Regarding Article, "Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both". <i>Circulation</i> , 2011, 123, .	1.6	0
553	Long-Term Effects of Percutaneous Coronary Intervention of the Totally Occluded Infarct-Related Artery in the Subacute Phase After Myocardial Infarction. <i>Circulation</i> , 2011, 124, 2320-2328.	1.6	34
554	CardioPulse Articles. <i>European Heart Journal</i> , 2011, 32, 1173-1181.	1.0	5
555	Clinical outcome of renal tubular damage in chronic heart failure. <i>European Heart Journal</i> , 2011, 32, 2705-2712.	1.0	174
556	Should Heart Failure and Atrial Fibrillation be Considered in Determining the Risk of Noncardiac Surgery?. <i>Circulation</i> , 2011, 124, 276-277.	1.6	0
557	Left Atrial Remodeling and Response to Valsartan in the Prevention of Recurrent Atrial Fibrillation. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 721-728.	1.3	14
558	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. <i>Circulation: Heart Failure</i> , 2010, 3, 314-325.	1.6	134

#	ARTICLE	IF	CITATIONS
559	Implantable Cardioverter-Defibrillators in Patients Hospitalized for Heart Failure With Chronically Reduced Left Ventricular Ejection Fraction. <i>American Journal of Therapeutics</i> , 2010, 17, e78-e87.	0.5	17
560	Epidemiology and patterns of care of patients admitted to Italian Intensive Cardiac Care units: the BLITZ-3 registry. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 450-461.	0.6	41
561	Evolution of renal function during and after an episode of cardiac decompensation: results from the Italian survey on acute heart failure. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 234-243.	0.6	18
562	Renin Inhibitors in Chronic Heart Failure: The Aliskiren Observation of Heart Failure Treatment Study in Context. <i>Clinical Cardiology</i> , 2010, 33, 536-541.	0.7	13
563	Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres. <i>Trials</i> , 2010, 11, 79.	0.7	45
564	Trial-generated profiles for implantation of electrical devices in outpatients with heart failure: real-world prevalence and 1-year outcome. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 82-91.	0.9	9
565	Early Response to Sibutramine in Patients Not Meeting Current Label Criteria: Preliminary Analysis of SCOUT Lead-in Period. <i>Obesity</i> , 2010, 18, 987-994.	1.5	17
566	Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 26-34.	2.2	17
567	Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. <i>Circulation</i> , 2010, 122, 597-602.	1.6	195
568	Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 65-72.	1.6	101
569	Evidence for the efficacy of ARBs across the cardiovascular continuum. <i>Current Medical Research and Opinion</i> , 2010, 26, 1203-1218.	0.9	13
570	The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. <i>European Journal of Heart Failure</i> , 2010, 12, 1229-1237.	2.9	45
571	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. <i>European Journal of Heart Failure</i> , 2010, 12, 557-565.	2.9	59
572	EUR-Observer Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2010, 12, 1076-1084.	2.9	340
573	Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. <i>European Journal of Heart Failure</i> , 2010, 12, 1345-1353.	2.9	75
574	Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2010, 12, 367-374.	2.9	78
575	Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. <i>Heart</i> , 2010, 96, 838-842.	1.2	31
576	The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. <i>European Journal of Heart Failure</i> , 2010, 12, 338-347.	2.9	129

#	ARTICLE	IF	CITATIONS
577	Age-Dependent Prognostic Significance of Atrial Fibrillation in Outpatients with Chronic Heart Failure: Data from the Italian Network on Congestive Heart Failure Registry. <i>Cardiology</i> , 2010, 116, 79-88.	0.6	13
578	The role of cardiac registries in evidence-based medicine. <i>European Heart Journal</i> , 2010, 31, 525-529.	1.0	118
579	Elevated Plasma Renin Activity Predicts Adverse Outcome in Chronic Heart Failure, Independently of Pharmacologic Therapy: Data From the Valsartan Heart Failure Trial (Val-HeFT). <i>Journal of Cardiac Failure</i> , 2010, 16, 964-970.	0.7	62
580	Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico "Atrial Fibrillation (GISSI-AF) trial. <i>American Heart Journal</i> , 2010, 159, 857-863.	1.2	22
581	Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: The VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). <i>American Heart Journal</i> , 2010, 160, 145-151.	1.2	33
582	Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. <i>American Heart Journal</i> , 2010, 160, 286-293.	1.2	60
583	Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. <i>New England Journal of Medicine</i> , 2010, 363, 905-917.	13.9	791
584	Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. <i>Lancet</i> , The, 2010, 375, 735-742.	6.3	2,064
585	Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. <i>Heart</i> , 2010, 96, 1909-1914.	1.2	31
586	Heart Failure Pilot protocol. <i>European Heart Journal</i> , 2010, 31, 2184-6.	1.0	2
587	Prescription at discharge of recommended treatments for secondary prevention in patients with ST-segment elevation myocardial infarction according to reperfusion strategies. Results from the IN-ACS outcome study. <i>Acute Cardiac Care</i> , 2009, 11, 222-228.	0.2	5
588	Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population. <i>Circulation</i> , 2009, 120, 835-842.	1.6	202
589	Predictors of Heart Failure in Patients With Stable Coronary Artery Disease. <i>Circulation: Heart Failure</i> , 2009, 2, 209-216.	1.6	53
590	Valsartan for Prevention of Recurrent Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 360, 1606-1617.	13.9	442
591	Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. <i>European Heart Journal</i> , 2009, 30, 2226-2232.	1.0	95
592	Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. <i>European Heart Journal</i> , 2009, 30, 1666-1673.	1.0	68
593	Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. <i>European Heart Journal</i> , 2009, 30, 2327-2336.	1.0	98
594	Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). <i>European Heart Journal</i> , 2009, 30, 1450-1456.	1.0	47

#	ARTICLE	IF	CITATIONS
595	SCOUT Trial Reports on the Safety Profile of Sibutramine in Patients with Cardiovascular Diseases. <i>Physician and Sportsmedicine</i> , 2009, 37, 95-97.	1.0	2
596	Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. <i>European Journal of Heart Failure</i> , 2009, 11, 68-76.	2.9	99
597	Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure. <i>European Journal of Heart Failure</i> , 2009, 11, 77-84.	2.9	19
598	Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-CHF): a Phase III, anaemia correction, morbidity-mortality trial. <i>European Journal of Heart Failure</i> , 2009, 11, 795-801.	2.9	107
599	Aldosterone status associated with insulin resistance in patients with heart failure--data from the ALOFT study. <i>Heart</i> , 2009, 95, 1920-1924.	1.2	29
600	Heart Rate in Coronary Syndromes and Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2009, 52, 38-45.	1.6	41
601	Where Are We With the Management of Hypertension? From Science to Clinical Practice. <i>Journal of Clinical Hypertension</i> , 2009, 11, 66-73.	1.0	13
602	Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. <i>Advances in Therapy</i> , 2009, 26, 469-487.	1.3	13
603	Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 735-748.	0.6	37
604	Levels of Circulating Pro-angiogenic Cells Predict Cardiovascular Outcomes in Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2009, 15, 747-755.	0.7	8
605	Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. <i>American Heart Journal</i> , 2009, 157, 957-970.	1.2	48
606	Clinical characteristics, management, and prognosis of octogenarians with acute heart failure admitted to cardiology wards: Results from the Italian Survey on Acute Heart Failure. <i>American Heart Journal</i> , 2009, 158, 126-132.	1.2	23
607	Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. <i>Lancet, The</i> , 2009, 374, 525-533.	6.3	391
608	Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2009, 11, 292-298.	2.9	102
609	A prospective multicentre observational study on the management of patients on oral anticoagulation undergoing coronary artery stenting: rationale and design of the ongoing warfarin and coronary stenting (WAR-STENT) registry. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 200-203.	0.6	10
610	Clinical implications and management of bleeding events in patients with acute coronary syndromes. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 677-686.	0.6	7
611	Effects of tolvaptan on dyspnoea relief from the EVEREST trials. <i>European Heart Journal</i> , 2009, 30, 2233-2240.	1.0	71
612	Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT). <i>EuroIntervention</i> , 2009, 5, 610-618.	1.4	6

#	ARTICLE	IF	CITATIONS
613	The Role of Thrombolysis in Acute Ischemic Stroke. Herz, 2008, 33, 498-506.	0.4	5
614	Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. European Journal of Clinical Pharmacology, 2008, 64, 627-634.	0.8	49
615	Predictors of Outcome and the Lack of Effect of Percutaneous Coronary Intervention Across the Risk Strata in Patients With Persistent Total Occlusion After Myocardial Infarction. JACC: Cardiovascular Interventions, 2008, 1, 511-520.	1.1	15
616	Sudden Cardiac Death in Patients With Stable Coronary Artery Disease and Preserved Left Ventricular Systolic Function. American Journal of Cardiology, 2008, 101, 457-461.	0.7	23
617	Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. American Journal of Cardiology, 2008, 101, 925-929.	0.7	22
618	Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure. Journal of the American College of Cardiology, 2008, 52, 1640-1648.	1.2	159
619	Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: Findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-3 trial. American Heart Journal, 2008, 155, 388-394.	1.2	26
620	High-risk myocardial infarction in the young: The VALSartan In Acute myocardial infarction (VALIANT) trial. American Heart Journal, 2008, 155, 706-711.	1.2	29
621	Usefulness of Right Ventricular Fractional Area Change to Predict Death, Heart Failure, and Stroke Following Myocardial Infarction (from the VALIANT ECHO Study). American Journal of Cardiology, 2008, 101, 607-612.	0.7	197
622	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET) trial. American Heart Journal, 2008, 155, 706-711.	6.3	1,442
623	Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 1223-1230.	6.3	1,178
624	Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 1231-1239.	6.3	954
625	Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo Study. European Heart Journal, 2008, 30, 56-65.	1.0	117
626	Global Secondary Prevention Strategies to Limit Event Recurrence After Myocardial Infarction. Archives of Internal Medicine, 2008, 168, 2194.	4.3	320
627	Clinical Implications of QRS Duration in Patients Hospitalized With Worsening Heart Failure and Reduced Left Ventricular Ejection Fraction. JAMA - Journal of the American Medical Association, 2008, 299, 2656.	3.8	168
628	Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. European Heart Journal, 2008, 29, 748-756.	1.0	102
629	Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace, 2008, 10, 403-411.	0.7	180
630	Depression worsens outcomes in elderly patients with heart failure: An analysis of 48,117 patients in a community setting. European Journal of Heart Failure, 2008, 10, 714-721.	2.9	46

#	ARTICLE	IF	CITATIONS
631	Response to The J-Point Revisited. Hypertension, 2008, 51, .	1.3	0
632	Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. Hypertension, 2008, 51, 48-54.	1.3	69
633	Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure. Circulation: Heart Failure, 2008, 1, 17-24.	1.6	340
634	Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Journal of Cardiovascular Pharmacology, 2008, 52, 393-402.	0.8	21
635	Modalities of treatment and 30-day outcomes of unselected patients older than 75 years with acute ST-elevation myocardial infarction: data from the BLITZ study. Journal of Cardiovascular Medicine, 2008, 9, 1045-1051.	0.6	5
636	Cardiogenic shock developing in the coronary care unit in patients with ST-elevation myocardial infarction. Journal of Cardiovascular Medicine, 2008, 9, 1023-1029.	0.6	17
637	Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management, 2008, 4, 223-234.	1.0	11
638	Management of Chronic Heart Failure Therapy in the Setting of Acute Heart Failure. , 2008, , 533-544.		0
639	Prediction of Mode of Death in Heart Failure. Circulation, 2007, 116, 392-398.	1.6	261
640	Coffee Consumption and Risk of Cardiovascular Events After Acute Myocardial Infarction. Circulation, 2007, 116, 2944-2951.	1.6	55
641	Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial. European Journal of Heart Failure, 2007, 9, 397-402.	2.9	72
642	FDA and CPMP Rulings on Subgroup Analyses. Cardiology, 2007, 107, 97-102.	0.6	30
643	Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. European Heart Journal, 2007, 28, 2915-2923.	1.0	128
644	Left bundle branch block as a risk factor for progression to heart failure. European Journal of Heart Failure, 2007, 9, 7-14.	2.9	142
645	Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure<SUBTITLE>The EVEREST Outcome Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2007, 297, 1319.	3.8	1,406
646	Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure<SUBTITLE>The EVEREST Clinical Status Trials</SUBTITLE>. JAMA - Journal of the American Medical Association, 2007, 297, 1332.	3.8	757
647	Efficacy of n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial. Journal of Cardiovascular Medicine, 2007, 8, S34-S37.	0.6	30
648	Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of) Tj ETQqO O O rgBT /Overlock 10 Tf 50 Cardiovascular Medicine, 2007, 8, 683-691.	0.6	16

#	ARTICLE	IF	CITATIONS
649	Prognostic Value of Serial Electrocardiographic Voltage and Repolarization Changes in Essential Hypertension: The HEART Survey Study. <i>American Journal of Hypertension</i> , 2007, 20, 997-1004.	1.0	39
650	Clinical, Neurohormonal, and Inflammatory Markers and Overall Prognostic Role of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure: Data From the Val-HeFT Heart Failure Trial. <i>Journal of Cardiac Failure</i> , 2007, 13, 797-804.	0.7	80
651	Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT. <i>International Journal of Cardiology</i> , 2007, 119, 48-53.	0.8	66
652	Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 1242-1249.	1.6	635
653	The Effect of Valsartan, Captopril, or Both on Atherosclerotic Events After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2006, 47, 726-733.	1.2	149
654	Coronary Intervention for Persistent Occlusion after Myocardial Infarction. <i>New England Journal of Medicine</i> , 2006, 355, 2395-2407.	13.9	635
655	Use of valsartan in post-myocardial infarction and heart failure patients.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, S19.	1.0	3
656	Incremental Prognostic Value of Changes in B-Type Natriuretic Peptide in Heart Failure. <i>American Journal of Medicine</i> , 2006, 119, 70.e23-70.e30.	0.6	95
657	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2006, 152, 86-92.	1.2	275
658	A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)â€Prevenzione scoring. <i>American Heart Journal</i> , 2006, 151, 754.e7-754.e17.	1.2	26
659	Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. <i>American Heart Journal</i> , 2006, 152, 500-508.	1.2	10
660	High pulse pressure and low mean arterial pressure: two predictors of death after a myocardial infarction. <i>Journal of Hypertension</i> , 2006, 24, 2377-2385.	0.3	32
661	Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 29-38.	0.6	42
662	Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 295-308.	1.3	25
663	Epidemiology of non-ST elevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study. <i>European Heart Journal</i> , 2006, 27, 393-405.	1.0	54
664	Programme to improve the use of beta-blockers for heart failure in the elderly and in those with severe symptoms: Results of the BRING-UP 2 Study. <i>European Journal of Heart Failure</i> , 2006, 8, 649-657.	2.9	25
665	Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunctionâ†. <i>European Journal of Heart Failure</i> , 2006, 8, 591-598.	2.9	111
666	The Seattle Heart Failure Model. <i>Circulation</i> , 2006, 113, 1424-1433.	1.6	1,744

#	ARTICLE	IF	CITATIONS
667	What Is the Optimal Reperfusion Strategy for Elderly Patients With Acute MI?. The American Journal of Geriatric Cardiology, 2006, 15, 14-18.	0.7	0
668	Angiotensin II antagonists in acute and post-acute myocardial infarction. , 2006, , 1-12.		0
669	Left Ventricular Assessment in Myocardial Infarction. Archives of Internal Medicine, 2005, 165, 2162.	4.3	18
670	Usefulness of Temporal Changes in Neurohormones as Markers of Ventricular Remodeling and Prognosis in Patients With Left Ventricular Systolic Dysfunction and Heart Failure Receiving Either Candesartan or Enalapril or Both. American Journal of Cardiology, 2005, 96, 698-704.	0.7	67
671	Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure. Circulation, 2005, 112, 1121-1127.	1.6	243
672	Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. European Journal of Heart Failure, 2005, 7, 904-909.	2.9	101
673	Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. New England Journal of Medicine, 2005, 352, 2581-2588.	13.9	721
674	Nationwide survey on acute heart failure in cardiology ward services in Italy. European Heart Journal, 2005, 27, 1207-1215.	1.0	215
675	Does eplerenone benefit postinfarction patients with heart failure and left ventricular systolic dysfunction?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 618-619.	3.3	0
676	Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. European Journal of Heart Failure, 2005, 7, 710-721.	2.9	111
677	Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. Canadian Journal of Physiology and Pharmacology, 2005, 83, 98-103.	0.7	14
678	Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. European Heart Journal, 2005, 26, 2114-2119.	1.0	28
679	Review of the new ESC guidelines for the pharmacological management of chronic heart failure. Country Review Ukraine, 2005, 7, J15-J20.	0.8	1
680	VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Expert Opinion on Pharmacotherapy, 2005, 6, 507-512.	0.9	25
681	Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal, 2005, 149, 548-557.	1.2	401
682	Different Normalizations for Body Size and Population Attributable Risk of Left Ventricular Hypertrophy: The MAVI Study. American Journal of Hypertension, 2005, 18, 1288-1293.	1.0	50
683	Determinants of Late-Onset Heart Failure in Myocardial Infarction Survivors: GISSI Prevenzione Trial Results. Revista Espanola De Cardiologia (English Ed), 2005, 58, 1266-1272.	0.4	0
684	Anemia in Patients With Heart Failure: Prevalence and Prognostic Role in a Controlled Trial and in Clinical Practice. Journal of Cardiac Failure, 2005, 11, 91-98.	0.7	118

#	ARTICLE	IF	CITATIONS
685	Temporal Trends in Survival and Hospitalizations in Outpatients With Chronic Systolic Heart Failure in 1995 and 1999. <i>Journal of Cardiac Failure</i> , 2005, 11, 270-278.	0.7	38
686	Rationale and Design of the Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). <i>Journal of Cardiac Failure</i> , 2005, 11, 260-269.	0.7	168
687	Metabolic Syndrome and Risk of Cardiovascular Events After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2005, 46, 277-283.	1.2	147
688	Global Secondary Prevention strategies to Limit event recurrence after myocardial infarction: the GOSPEL study. A trial from the Italian Cardiac Rehabilitation Network: rationale and design. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 555-561.	3.1	13
689	Symptomatic despite Multiple Drug Therapy: Where do you Turn Next?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2005, 6, .	1.0	0
690	Clinical characteristics and outcome of diabetic patients with acute myocardial infarction. Data from the BLITZ-1 study. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2005, 6, 374-83.	0.1	10
691	Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease The Task Force on ACE-inhibitors of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1454-1470.	1.0	249
692	Prognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial Infarction. <i>Circulation</i> , 2004, 110, 2349-2354.	1.6	402
693	Expert consensus document on β -adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1341-1362.	1.0	465
694	N-Terminal Pro-Brain Natriuretic Peptide on Admission Has Prognostic Value Across the Whole Spectrum of Acute Coronary Syndromes. <i>Circulation</i> , 2004, 110, 128-134.	1.6	281
695	Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. <i>European Journal of Heart Failure</i> , 2004, 6, 937-945.	2.9	87
696	The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. <i>European Heart Journal</i> , 2004, 25, 292-299.	1.0	319
697	The "real" woman with heart failure. Impact of sex on current in-hospital management of heart failure by cardiologists and internists. <i>European Journal of Heart Failure</i> , 2004, 6, 769-779.	2.9	40
698	Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. <i>European Journal of Heart Failure</i> , 2004, 6, 635-641.	2.9	214
699	Left atrium remodeling after acute myocardial infarction (results of the GISSI-3 Echo Substudy). <i>American Journal of Cardiology</i> , 2004, 93, 1156-1159.	0.7	26
700	RAAS Inhibitors in the Cardiovascular Continuum: What is Still Missing?. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 311-320.	1.3	2
701	Valsartan for the treatment of heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 181-193.	0.9	4
702	An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. <i>European Heart Journal</i> , 2004, 25, 1911-1919.	1.0	126

#	ARTICLE	IF	CITATIONS
703	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi3n de la angiotensina en la enfermedad cardiovascular. Revista Espanola De Cardiologia, 2004, 57, 1213-1232.	0.6	8
704	Doppler-derived mitral deceleration time as a strong prognostic marker of left ventricular remodeling and survival after acute myocardial infarction. Journal of the American College of Cardiology, 2004, 43, 1646-1653.	1.2	137
705	Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. New England Journal of Medicine, 2004, 351, 1285-1295.	13.9	1,712
706	Commentary 1. Evidence-based Cardiovascular Medicine, 2004, 8, 96-97.	0.0	0
707	Participation versus education: The GISSI story and beyond. American Heart Journal, 2004, 148, 222-229.	1.2	20
708	The long pentraxin PTX3: from innate immunity to ischemic heart disorders. International Congress Series, 2004, 1262, 63-66.	0.2	0
709	In-hospital and one-year outcomes of patients with high-risk acute myocardial infarction treated with thrombolysis or primary coronary angioplasty. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2004, 5, 136-45.	0.1	3
710	Prescription patterns of diuretics in chronic heart failure: A contemporary background as a clue to their role in treatment. Journal of Cardiac Failure, 2003, 9, 210-218.	0.7	25
711	Survival and hospitalization in heart failure patients with or without diabetes treated with ð-blockers. Journal of Cardiac Failure, 2003, 9, 192-202.	0.7	51
712	Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the delapril remodeling after acute myocardial infarction (DRAM1) trial. American Heart Journal, 2003, 146, 133A-140A.	1.2	8
713	Current presentation and management of heart failure in cardiology and internal medicine hospital units: a tale of two worldsthe TEMISTOCLE study. American Heart Journal, 2003, 146, 735.	1.2	115
714	Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal of Medicine, 2003, 349, 1893-1906.	13.9	2,240
715	Ergometric score systems after myocardial infarction: Prognostic performance of the Duke Treadmill Score, Veterans Administration Medical Center Score, and of a novel score system, GISSI-2 Index, in a cohort of survivors of acute myocardial infarction. American Heart Journal, 2003, 145, 475-483.	1.2	16
716	Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. British Heart Journal, 2003, 89, 299-305.	2.2	76
717	Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation, 2003, 107, 1278-1283.	1.6	786
718	VALsartan In Acute myocardial infarcTion (VALIANT) trial: baseline characteristics in context. European Journal of Heart Failure, 2003, 5, 537-544.	2.9	76
719	Determinants of use and outcomes of invasive coronary procedures in acute coronary syndromes: results from ENACT. European Heart Journal, 2003, 24, 613-622.	1.0	24
720	Epidemiology of acute myocardial infarction in the Italian CCU network The BLITZ Study. European Heart Journal, 2003, 24, 1616-1629.	1.0	111

#	ARTICLE	IF	CITATIONS
721	Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. <i>European Heart Journal</i> , 2003, 24, 1727-1734.	1.0	52
722	Hypertrophy at ECG and its regression during treatment survey (HEART survey). Rationale, design and baseline characteristics of patients. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003, 4, 479-83.	0.1	1
723	Intraventricular conduction defects in patients with congestive heart failure: left but not right bundle branch block is an independent predictor of prognosis. A report from the Italian Network on Congestive Heart Failure (IN-CHF database). <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003, 4, 607-13.	0.1	12
724	Impact of diabetes on the current in-hospital management of heart failure. From the TEMISTOCLE study. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003, 4, 685-94.	0.1	2
725	Comparative Measurement of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide in Ambulatory Patients with Heart Failure. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002, 40, 761-3.	1.4	68
726	Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure. <i>Circulation</i> , 2002, 106, 2454-2458.	1.6	279
727	Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction. <i>Circulation</i> , 2002, 105, 1897-1903.	1.6	1,213
728	Prognosis of Inappropriate Left Ventricular Mass in Hypertension. <i>Hypertension</i> , 2002, 40, 470-476.	1.3	139
729	Clinical value of 12-lead electrocardiography to predict the long-term prognosis of gissi-1 patients. <i>Journal of the American College of Cardiology</i> , 2002, 39, 1594-1600.	1.2	24
730	Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1414-1421.	1.2	331
731	The Angiotensin-receptor Blockers: From Antihypertensives to Cardiovascular All-round Medications in 10 Years?. <i>Blood Pressure</i> , 2002, 11, 328-338.	0.7	9
732	Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: Data from a large nationwide cardiology database (IN-CHF Registry). <i>American Heart Journal</i> , 2002, 143, 45-55.	1.2	162
733	Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: A report from the Italian network on congestive heart failure. <i>American Heart Journal</i> , 2002, 143, 398-405.	1.2	681
734	Variations in lipoprotein levels after myocardial infarction and unstable angina: the LATIN trial. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2002, 3, 587-92.	0.1	9
735	Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1829-1835.	1.2	325
736	Heterogeneity of left ventricular remodeling after acute myocardial infarction: Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-3 Echo Substudy. <i>American Heart Journal</i> , 2001, 141, 131-138.	1.2	92
737	The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial. <i>American Heart Journal</i> , 2001, 142, 375-377.	1.2	15
738	Absence of slowest oscillations in short term heart rate variability of post-myocardial infarction patients. GISSI-3 arrhythmias substudy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2001, 90, 127-131.	1.4	3

#	ARTICLE	IF	CITATIONS
739	Debate: Should statin be used in patients with heart failure?. , 2001, 2, 266.		11
740	Precipitating factors and decision-making processes of short-term worsening heart failure despite "optimal" treatment (from the IN-CHF Registry). American Journal of Cardiology, 2001, 88, 382-387.	0.7	131
741	Cardiac protection by pharmacological modulation of inflammation. Expert Opinion on Investigational Drugs, 2001, 10, 1913-1924.	1.9	3
742	HEART FAILURE: Treatment strategies for heart failure: beta blockers and antiarrhythmics. British Heart Journal, 2001, 85, 97-103.	2.2	3
743	Spectral and bidirectional filters give different results for signal-averaged ECG analysis in patients with postmyocardial infarction. Journal of Electrocardiology, 2000, 33, 233-240.	0.4	2
744	The role of myocardial viability in deriving benefit from reestablishing infarct-related artery flow after acute myocardial infarction. Progress in Cardiovascular Diseases, 2000, 42, 455-470.	1.6	10
745	Comparison of one-year outcome in women versus men with chronic congestive heart failure. American Journal of Cardiology, 2000, 86, 353-357.	0.7	61
746	Secondary prevention: improving outcomes following myocardial infarction. British Heart Journal, 2000, 84, 5i-7.	2.2	3
747	Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. American Heart Journal, 2000, 139, 609-617.	1.2	113
748	Epidemiologic study of use of resources in patients with unstable angina: The EARISA Registry. American Heart Journal, 2000, 140, 253-261.	1.2	14
749	Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal, 2000, 140, 727-750.	1.2	162
750	PTX3, A Prototypical Long Pentraxin, Is an Early Indicator of Acute Myocardial Infarction in Humans. Circulation, 2000, 102, 636-641.	1.6	384
751	Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. Journal of the American College of Cardiology, 2000, 35, 1801-1807.	1.2	156
752	Electrocardiographic evolutionary changes and left ventricular remodeling after acute myocardial infarction. The Investigators and Institutions participating in the GISSI-3 Echo Substudy are listed in the Appendix.. Journal of the American College of Cardiology, 2000, 35, 127-135.	1.2	44
753	The Heart in Diabetes: Results of Trials. , 2000, , 55-65.		0
754	Introducing new treatments in clinical practice: the Italian approach to beta Blockers in heart failure. Heart, 1999, 81, 453-454.	1.2	15
755	Electrocardiographic patterns in acute inferior myocardial infarction with and without right ventricle involvement: Classification, diagnostic and prognostic value, masking effect. Clinical Cardiology, 1999, 22, 37-44.	0.7	18
756	Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE Multicenter Trial. American Heart Journal, 1999, 138, 247-253.	1.2	136

#	ARTICLE	IF	CITATIONS
757	How to use ACE-inhibitors, β -blockers, and newer therapies in AMI. American Heart Journal, 1999, 138, S183-S187.	1.2	8
758	Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents. American Heart Journal, 1999, 137, 443-452.	1.2	56
759	Predischarge Two-Dimensional Echocardiographic Evaluation of Left Ventricular Thrombosis After Acute Myocardial Infarction in the GISSI-3 Study 11GISSI-3 is supported by The Associazione Nazionale Cardiologi Ospedalieri (ANMCO) and Istituto di Ricerche Farmacologiche "Mario Negri." American Journal of Cardiology, 1998, 81, 822-827.	0.7	130
760	Very early administration of ACE-inhibitors in acute myocardial infarction. International Journal of Cardiology, 1998, 65, S61-S64.	0.8	1
761	Ramipril following acute MI attenuated LV remodeling. Evidence-based Cardiovascular Medicine, 1998, 2, 13.	0.0	1
762	WITHIN-PATIENT VARIABILITY OF HORMONE AND CYTOKINE CONCENTRATIONS IN HEART FAILURE. Pharmacological Research, 1998, 37, 213-217.	3.1	25
763	Cost-Effectiveness Analysis of Early Lisinopril Use in Patients With Acute Myocardial Infarction. Pharmacoeconomics, 1998, 13, 337-346.	1.7	14
764	Administration of thrombolytic therapy to 17,944 patients with acute myocardial infarction: The GISSI-3 database. American Heart Journal, 1998, 135, 443-448.	1.2	6
765	Ten-Year Follow-Up of the First Megatrial Testing Thrombolytic Therapy in Patients With Acute Myocardial Infarction. Circulation, 1998, 98, 2659-2665.	1.6	162
766	A Comparison of the Early Outcome of Acute Myocardial Infarction in Women and Men. New England Journal of Medicine, 1998, 338, 8-14.	13.9	262
767	The Heart in Diabetes: Results of Trials. , 1998, , 51-60.		0
768	Treatment of acute myocardial infarction today. American Heart Journal, 1997, 134, s9-s14.	1.2	2
769	Elevated cardiac troponin T levels were associated with increased 30-day mortality in patients presenting with acute myocardial ischemia. Evidence-based Cardiovascular Medicine, 1997, 1, 39-40.	0.0	0
770	The GISSI Story (1983-1996): A Comprehensive Review. Journal of Interventional Cardiology, 1997, 10, 3-28.	0.5	6
771	Pericardial involvement in acute myocardial infarction in the post-thrombolytic era: Clinical meaning and value. Clinical Cardiology, 1997, 20, 327-331.	0.7	15
772	Effect of the ACE Inhibitor Lisinopril on Mortality in Diabetic Patients With Acute Myocardial Infarction. Circulation, 1997, 96, 4239-4245.	1.6	188
773	Factors influencing the non-administration of thrombolytic therapy in 17944 patients randomized to GISSI-3 trial. Journal of the American College of Cardiology, 1996, 27, 246.	1.2	2
774	RECPAM (Recursive Partition and Amalgamation), a novel statistical approach for early prediction of outcome in patients with acute myocardial infarction. Journal of the American College of Cardiology, 1996, 27, 250.	1.2	1

#	ARTICLE	IF	CITATIONS
775	Prognostic value of a history of hypertension in 11483 patients with acute myocardial infarction treated with thrombolysis. <i>Journal of Hypertension</i> , 1996, 14, 743-750.	0.3	50
776	Myocardial Infarction: When and How Should We Initiate Treatment with ACE Inhibitors?. <i>Cardiology</i> , 1996, 87, 16-22.	0.6	4
777	Trends and determinants of calcium antagonist usage after acute myocardial infarction (the GISSI) Tj ETQq1 1 0.784314 rgBT _g /Overlo	0.7	0
778	Reproducibility of wall motion score and its correlation with left ventricular ejection fraction in patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 1996, 78, 855-858.	0.7	24
779	Diltiazem improves left ventricular systolic function following acute myocardial infarction treated with streptokinase. <i>American Journal of Cardiology</i> , 1996, 78, 1049-1052.	0.7	13
780	Prognostic Significance of Heart Rate Variability in Post-Myocardial Infarction Patients in the Fibrinolytic Era. <i>Circulation</i> , 1996, 94, 432-436.	1.6	204
781	ACE Inhibitor Use in Patients With Myocardial Infarction. <i>Circulation</i> , 1995, 92, 3132-3137.	1.6	190
782	A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent. <i>Journal of the American College of Cardiology</i> , 1994, 24, 600-607.	1.2	98
783	Predictors of nonfatal reinfarction in survivors of myocardial infarction after thrombolysis. <i>Journal of the American College of Cardiology</i> , 1994, 24, 608-615.	1.2	48
784	Frequency of predischarge ventricular arrhythmias in postmyocardial infarction patients depends on residual left ventricular pump performance and is independent of the occurrence of acute reperfusion. <i>Journal of the American College of Cardiology</i> , 1994, 23, 290-295.	1.2	7
785	Ethical committees and noninformed consent. <i>Journal of the American College of Cardiology</i> , 1994, 24, 1178.	1.2	0
786	Cytokines in Acute Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 23, 1-6.	0.8	90
787	Cytokines in Acute Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 23, 1.	0.8	129
788	Comparison of frequency, diagnostic and prognostic significance of pericardial involvement in acute myocardial infarction treated with and without thrombolytics. <i>American Journal of Cardiology</i> , 1993, 71, 1377-1381.	0.7	56
789	Influence of diabetes on mortality in acute myocardial infarction: Data from the GISSI-2 study. <i>Journal of the American College of Cardiology</i> , 1993, 22, 1788-1794.	1.2	242
790	The Risk of Stroke in Patients with Acute Myocardial Infarction after Thrombolytic and Antithrombotic Treatment. <i>New England Journal of Medicine</i> , 1992, 327, 1-6.	13.9	329
791	GISSI Trials in Acute Myocardial Infarction. <i>Chest</i> , 1990, 97, 146S-150S.	0.4	7
792	The Ideal Thrombolytic Agent: GISSI-2 and ISIS-3. <i>Journal of Interventional Cardiology</i> , 1990, 3, 157-168.	0.5	0

#	ARTICLE	IF	CITATIONS
793	The case of gissi in changing the attitudes and practice of Italian cardiologists. <i>Statistics in Medicine</i> , 1990, 9, 17-27.	0.8	24
794	Therapeutic Drug Monitoring of Antiarrhythmic Drugs. <i>Clinical Pharmacokinetics</i> , 1990, 18, 91-103.	1.6	10
795	One-year prognosis of primary ventricular fibrillation complicating acute myocardial infarction. <i>American Journal of Cardiology</i> , 1989, 63, 1174-1178.	0.7	82
796	Flecainide Half-Life Prolongation in 2 Patients with Congestive Heart Failure and Complex Ventricular. <i>Clinical Pharmacokinetics</i> , 1988, 14, 187-188.	1.6	13
797	Amiodarone and desethylamiodarone: Plasma concentrations, therapeutic effects and side effects. <i>Journal of the American College of Cardiology</i> , 1988, 11, 209.	1.2	4
798	In-Hospital Prognosis of Patients with Acute Myocardial Infarction Complicated by Primary Ventricular Fibrillation. <i>New England Journal of Medicine</i> , 1987, 317, 257-261.	13.9	118
799	Cardiac Amyloidosis Involving the Conduction System and the Aortocoronary Neuroreceptors. <i>Chest</i> , 1986, 90, 619-621.	0.4	15
800	Two False-negative Responses to the Ajmaline Test in the Wolff-Parkinson-White Syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1985, 8, 832-837.	0.5	2
801	Incessant atrioventricular nodal reciprocating tachycardia successfully treated with intravenous amiodarone. <i>American Heart Journal</i> , 1985, 110, 159-161.	1.2	3
802	Amiodarone distribution in human tissues after sudden death during holter recording. <i>American Journal of Cardiology</i> , 1983, 52, 217-218.	0.7	35
803	Is it time to introduce anti-inflammatory drugs into secondary cardiovascular prevention: evidence from clinical trials?. <i>Vessel Plus</i> , 0, 2021, .	0.4	2
804	Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10â€™220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. <i>European Journal of Preventive Cardiology</i> , 0, , .	0.8	3